RxDoctor Payments Data

Taylor Gwin, MD

Vascular Surgery · Baton Rouge, LANPI 1093974099

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,569 of the $6,544 with a category attached, or 85.1%. It is spread thinly across 36 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,717 and has fallen 81.9% since, to $311 in 2025.

$6,544in general payments, 2019–2025

Across 162 payments — averaging $40.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$2K
  • W. L. Gore & Associates, Inc.$1K
  • Endologix LLC$822
  • Inari Medical, Inc.$297
  • Smith+Nephew$249
  • Boston Scientific$242
  • plus $2K from 30 others

What the payments were for

  • Travel & lodging$93614%
  • Food & beverage$5,56985%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,544 in reported general payments places this provider in the 55th percentile of 65 vascular surgery providers in Louisiana.

See all vascular surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$191,607
Medicare patients
435
Services billed
1,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban36$34,465
EliquisApixaban29$19,736
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen133$1,670
ClopidogrelClopidogrel Bisulfate129$797
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen79$591
Nifedipine ErNifedipine14$320
Cilostazol24$226
Gabapentin28$205
Duloxetine Hcl19$178
Doxycycline Hyclate11$144
Warfarin Sodium23$95
Amitriptyline Hcl12$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$217$34,46536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 65 vascular surgery providers in Louisiana.

Other vascular surgery in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →